Telix Pharmaceuticals (NASDAQ: $TLX) and St Vincent’s Hospital have started dosing the first patients in OPTIMAL‑e, a clinical trial bringing their next‑generation PSMA‑targeted radioligand therapy…
July 08, 2026
MAIA Biotechnology Reports 90.5% Disease Control Rate in Third-Line NSCLC from THIO-101 Part C Expansion Trial
MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on targeted immunotherapies for cancer, reported positive initial efficacy data on July 8, 2026…
Legend Biotech Corporation (NASDAQ: LEGN) achieved a major technological milestone on June 14, 2026, by establishing clinical proof-of-concept for its novel oncology asset, LB2501. The…
Tango Therapeutics Inc. (NASDAQ: TNGX) just delivered the kind of data that can reset a small‑cap oncology name, with shares soaring over 30% after new…
Aptevo Therapeutics Inc. (NASDAQ: APVO) and Niowave Inc. are forming a 50/50 partnership to develop up to three radiopharmaceutical cancer drugs, giving both companies a…
Alpha Tau Medical (NASDAQ: DRTS) has hit a key milestone in its pancreatic cancer program, successfully treating the first pancreatic cancer patient in Europe with its…
April 21, 2026
BriaCell Highlights Potent Preclinical Anti‑Cancer Activity For Next‑Gen Bria‑OTS+ Platform
BriaCell Therapeutics (NASDAQ: BCTX) presented new preclinical data showing that its next‑generation Bria‑OTS+ off‑the‑shelf immunotherapy platform triggers strong, coordinated immune responses and robust tumor‑killing activity across…
Caris Life Sciences (NASDAQ: CAI) has introduced a multimodal, AI‑powered “immunotherapy treatment selection” signature for a subset of non‑small cell lung cancer (NSCLC) patients who are…
March 17, 2026
Candel Therapeutics Gains Momentum as Lead Cancer Therapy Advances Across Multiple Trials
Candel Therapeutics, Inc. (NASDAQ: CADL) continues to advance its lead oncology program following updated mid-stage clinical data for its investigational therapy CAN-2409 (aglatimagene besadenovec). The…
February 24, 2026
Cancer Immunotherapy Breakthroughs Are Transforming Oncology and Driving Biotech Growth
Cancer immunotherapy has become one of the most important breakthroughs in modern medicine, reshaping how cancer is treated and creating significant commercial opportunities for leading…
January 07, 2026
BBOT’s ON/OFF Biology: A Game-Changer in Oncology
BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) unveiled promising updates across its oncology pipeline, solidifying its position as a leader in innovative cancer therapies. The standout…
Cencora (NYSE: COR) is moving forward with plans to acquire majority control of OneOncology, a U.S.-based oncology care network, in a transaction that values the…